Withdraw approval for Tamiflu until NICE has full data2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8415 (Published 12 December 2012) Cite this as: 2012;345:e8415
- Fiona Godlee, editor, BMJ
I wanted to congratulate you on all you have achieved with the National Institute for Health and Clinical Excellence (NICE) in the past 10 years, now that your time as its chairman is coming to an end. However, I also wanted to ask you about something that I have found increasingly puzzling. Why does NICE not require access to all the clinical trial data on a drug when it is making a decision to approve the drug for purchase by the NHS? And given the European Ombudsman’s ruling against such data being commercial in confidence, why does NICE not make public the full information on which its decisions are based?
I ask this because, as you will know, the BMJ has been trying to help the Cochrane Collaboration gain full access to the data on oseltamivir (Tamiflu) in order to complete the systematic review commissioned by the National Institute for Health Research (NIHR) in 2009.1 2 3 Roche gave a public commitment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial